Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases
The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
1. A method for treating a bacterial infection caused by Clostridium difficile , comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
or a pharmacologically acceptable salt thereof.
2. The method according to claim 1 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered by an infusion.
3. The method according to claim 2 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 3 mg/(kg body weight×h).
4. The method according to claim 3 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 1.5 mg/(kg body weight×h).
5. The method according to claim 4 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of from 0.4 to 0.75 mg/(kg body weight×h).
6. The method according to claim 5 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered at an infusion rate of 0.5 mg/(kg body weight×h).
7. The method according to claim 1 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of from 20 min to 24 h per day.
8. The method according to claim 7 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of from 4 h to 12 h per day.
9. The method according to claim 8 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered over a period of 12 h per day.
10. The method according to claim 1 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily for a period of up to 10 days.
11. The method according to claim 10 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily for a period of 10 days.
12. The method according to claim 1 , wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily at a dose of 6 mg/kg.
13. The method according to claim 1 , wherein the compound, or a pharmacologically acceptable salt thereof, is a sodium salt of the compound.
14. The method according to claim 1 , wherein the bacterial infection caused by Clostridium difficile is an intestinal disease caused by Clostridium difficile.
15. The method according to claim 14 , wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.
16. The method according to claim 1 , wherein the bacterial infection caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.
17. A method for treating an intestinal disease caused by Clostridium difficile , comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
or a pharmacologically acceptable salt thereof, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily at an infusion rate of 0.5 mg/(kg body weight×h) over a period of 12 h per day for a period of 10 days.
18. The method according to claim 17 , wherein the intestinal disease caused by Clostridium difficile is diarrhea, colitis, or pseudomembranous colitis.
19. The method according to claim 17 , wherein the intestinal disease caused by Clostridium difficile is ileus, toxic megacolon, fulminant colitis, colonic perforation or need for colectomy.
20. The method according to claim 17 , wherein the compound, or a pharmacologically acceptable salt thereof, is a sodium salt of the compound.